Crista Galli Ventures — 2022 Investments
5 investments dated 2022 · listed companies and verified rows first · show all
52North Health develops NeutroCheck, a diagnostic tool that identifies neutropenia in chemotherapy patients presenting with fever, enabling risk stratification and reducing unnecessary emergency department visits.
BiotechDigital HealthHealthtechMedical DevicesCambridge, GB
Co-investorsMeridian Health VenturesCambridge Angels groupFuture Planet CapitalParkwalk AdvisorsSie VenturesCambridge Innovation Capital+2 more
Adni operates a platform connecting healthcare workers with employment opportunities while providing tools for credential management and professional networking; the platform also serves healthcare employers seeking to identify and screen clinical talent through AI-powered recruiting capabilities.
AI & Machine LearningHealthtechMarketplacesSaaSSan Francisco, US
Anthony Scarpone-Lambert(Founder)inJennifferre Mancillas(Founder)inBrendan Doms(CTO)in
Co-investorsAugment VenturesFlare Capital PartnersLighthouse Network Ventures LlcY CombinatorFresco CapitalGaingels+2 more
Anja Health provides cord blood banking and stem cell storage services from umbilical cords and placentas for families.
BiotechFemTechHealthtechMedical DevicesWellness & FitnessNew York City, US
Kathryn Cross(Founder)inAustin Yoshino(Head of Growth)Manuella Widjaja(Operations Lead)Katie Wilkinson(Marketing)viren Shetty(advisor)
Co-investorsSeven Seven SixY CombinatorGaingelsHarvest Venture PartnersVentureSouqElectric Ant+4 more
Apryl (Progyny Global) offers a fertility benefits platform that connects employees with fertility experts, clinics, and treatments including IVF, egg and sperm freezing, surrogacy, adoption, and menopause management.
Digital HealthFemTechHR Tech
Co-investorsAFI VenturesAtlanticAuxxoJazzya InvestmentsMyelin VCSie Ventures+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.













__Twitter.png)







